GleamWall
中文EN

LUCY Innovative Eyewear Inc

Ophthalmic Goods · Nasdaq · SEC CIK 1808377 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY56.9%
TTM net income YoY-3.7%
TTM EPS YoY42.4%
Revenue 3-yr CAGR83.9%
Net income 3-yr CAGR—

Margins

Gross margin22.7%
Operating margin—
Net margin-216.8%
FCF margin—
EBITDA margin—

Returns

ROE-92.4%
ROA-84.0%
ROIC (approx.)—
Asset turnover0.39x

Leverage & solvency

Liabilities / assets10.2%
Debt / equity0.00x
Current ratio9.12x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-9.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$2.66M$1.64M
Cost of revenue$2.09M$1.42M
Gross profit$567,451$215,190
R&D expense$725,388$819,387
SG&A expense$5.23M$4.47M
Net income-$7.59M-$7.77M
EPS (basic)-1.90-5.19
EPS (diluted)-1.90-5.19
Weighted avg. shares (diluted)3.99M1.50M
Balance sheet
Cash & equivalents$6.51M$2.63M
Receivables$142,152$107,918
Inventory$1.75M$831,757
Current assets$9.44M$9.24M
PP&E, net$61,777$107,562
Intangibles$559,968$451,302
Total assets$10.14M$9.84M
Current liabilities$1.05M$737,718
Total liabilities$1.07M$743,168
Shareholders' equity$9.07M$9.10M
Shares outstanding5.48M2.45M
Cash flow statement
Operating cash flow-$7.28M-$6.74M
Capital expenditure$72,513$62,203
Free cash flow-$7.35M-$6.80M
Investing cash flow$4.48M-$5.16M
Financing cash flow$6.68M$10.24M
Depreciation & amortization$66,788$109,489
Stock-based compensation$738,170$774,788

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.